



Career Development Awards FAQ Sheet

- 1. Which Grant should I apply for?** The **Pediatric Epilepsy Research Foundation® (PERF®)-CNS Elterman Research Grant** supports clinical or basic science research while the **Pediatric Epilepsy Research Foundation® (PERF®)-CNS Shields Research Grant** supports translational or clinical research. The applicant should carefully review criteria for each Grant and then select one preference on the face page. All applicants are now required to complete the Appendix.
- 2. Is there a difference in relevant scientific agenda for the PERF®-CNS Elterman vs the PERF®-CNS Shields award?** No. However, the Shields grant needs to have a clinical component, whereas the Elterman grant does not. **The PERF®-CNS grants do not need to be related to epilepsy.** Currently funded research is disqualified for the PERF Elterman and Shields Grants except for an NIH KL2, K12, R25 or T32 grant. Candidates are eligible for the PERF Elterman and Shields Grants if they have received an NIH KL2, K12, R25 or T32 grant.
- 3. Can CNS members who previously received a CNS or CNF grant or award apply for a PERF®-CNS Elterman/Shields research grant?** Yes, the committee will consider every application. However, when considering two or more outstanding proposals, the committee may give preference to the applicant without prior funding from CNS, CNF, or PERF.
- 4. Indirect Costs** including facilities or administrative costs are not funded. A letter from the Investigator's Sponsored Projects office is not required. However, at least one reference letter should include a yellow highlighted statement of the applicant's eligibility for the Award and should document the willingness of the institution to accept the award without indirect costs and provision of sufficient protected time to perform the research described in the application. These highlighted statements are often included in a letter from the applicant's Section Chief or Department Chair.
- 5. When does the funding cycle begin?** Award recipients will be notified by the end of June of the granting year. The funding cycle begins September 1 contingent on execution of the grant agreement and IRB approval of the research project.
- 6. CNS Annual Meeting Abstract Requirement.** During the grant period, or in the following year (i.e. April), the Awardee will be required to submit an abstract for presentation to the CNS Annual Meeting. Should the abstract be accepted for publication, the Awardee will receive a fee waiver to cover the cost of meeting registration. We also anticipate that projects funded by this grant will lead to publication of original research in peer-reviewed journals. The abstract for the poster/platform should be appropriately modified to conform with the CNS Meeting Guidelines (Objective, Methods, Results, Conclusions).
- 7. The Grant Application.** The applicant should follow the directions and suggested format indicated in the **Career Development Grants/Procedure for All Grants.**

A. **Core Section**

1. **Face Page.** This is page 1 & 2 of the application. Include investigator's post-nominal degree(s) after name.

2. **Table of Contents.** This is page 3 of the application with the format as below:

Table of Contents

Face Page.....	1-2
Table of Contents.....	3
Abstract.....	4
Specific Aims.....	5
etc.....	etc.

3. **Abstract.** Include a brief (300 words maximum) background with preliminary data (published and unpublished), hypotheses, goal, aims, and anticipated outcomes.
4. **Specific Aims.** Include a succinct background. Include the hypotheses, methods, and anticipated outcome(s) for each Aim.
5. **Work by Others.** Includes background of the disease and data that applies to your question/hypothesis. This includes work done outside of the applicant's laboratory or clinical research program.
6. **Work by Investigator.** Includes any preliminary scientific data and/or data that shows the feasibility of the proposed experiments.
8. **Research plan.** The proposed research should be feasible, and experiments should be completed by the time funding ends.
9. **References.** Two-page limit.
10. **Investigator Biographical Sketch.** Use the standard NIH Biosketch template, <https://grants.nih.gov/grants/forms/biosketch.htm> , not to exceed 5 pages.
11. **Letters of Recommendation.**
- (a) Submit one letter of recommendation from the director of the applicant's child neurology division and one letter from his/her scientific advisor. Two additional optional letters of recommendation or support may be included.
 - (b) At least one reference letter should include a **yellow highlighted** statement of the applicant's eligibility for the Award and should document the willingness of the institution to accept the award without indirect costs and provision of sufficient protected time to perform the research described in the application. These highlighted statements are often included in a letter from the applicant's Section Chief or Department Chair.

B. **Appendix Section.** All applicants are required to include this section in their application. Page limitations are indicated in the **Career Development Grants/Procedure for All Grants**. There are no page limitations for appendix materials such as Human Subjects, Budget and justification, etc. However, these sections should be succinct and MUST NOT contain unrelated information such as Research plan,

figures, data, etc.

- i. **Human Subjects.** If applicable, IRB approval and IRB-approved informed consent forms will be required before funds are released. This section should provide a description of the proposed involvement of human subjects and may contain as applicable the following information. Type N/A if no human subjects are used in the proposed experiments.
 - **Protections for Human Subjects.** For research that involves human subjects but does not involve one of the six categories of research that are exempt under [45 CFR Part 46](#), the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials.
 - **Inclusion of Women, Minorities, and Children.** When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed.
- ii. **Vertebrate animals:** If applicable, the Awardee's institutional IACUC approval will be required before funds are released. This section should provide a description of the proposed involvement of vertebrate animals and may contain as applicable the following information: The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. Type N/A if no vertebrate animals are used in the proposed experiments.
- iii. **Budget, Period of Support, Justification.** Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
- iv. **Resources.** Specify the facilities to be used for the conduct of the proposed research. Indicate the performance sites and describe capacities, pertinent capabilities, relative proximity and extent of availability to the project. List the most important equipment items already available for this project, noting the location and pertinent capabilities of each.
- v. **Performance Sites and Key Personnel.** Detail where the experiments will be performed. List the names and institutions of any study investigators and

collaborators and their role in the project.

- vi. **NIH Biographical Sketches for Any Other Additional Key Personnel.** The NIH Biosketch for any Key Personnel/Mentors should not exceed 5 pages.

7. The Research Grant Review

The CNS grant review committee consists of both clinicians and physician-scientists with a wide variety of backgrounds. Applicants should therefore write succinctly and clearly describe all scientific terms and experiments. Abbreviations should be identified in their first instance and can then be used throughout the proposal. The Applicant should consider that multiple abbreviations can become confusing.

The reviewers will consider the following and provide constructive feedback to the applicant, when indicated: significance, investigator, innovation, approach, environment, and other score influences, including references, human subjects, animal welfare, etc.

Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Investigator. Is the investigator well suited to the project? Do they have appropriate experience and training? If the project is collaborative, do the investigators have complementary and integrated expertise; are their leadership approach, governance, and organizational structure appropriate for the project?

Innovation. Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Approach: Is the overall strategy, methodology, and analysis well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility? Will particularly risky aspects be managed effectively?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (exclusion) of children, justified in terms of the scientific goals and research strategy proposed?

Environment: Will the scientific environment in which the work will be done contribute to the probability of success? Is the institutional support, protected time for research endeavors, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Budget: Will the proposed research be completed with the funds and within the proposed time frame?